04:35 AM EST, 12/10/2025 (MT Newswires) -- Denali Therapeutics ( DNLI ) said Wednesday that it has priced its underwritten public offering of 9.1 million shares at $17.50 per share and pre-funded warrants to purchase about 2.3 million at $17.49 each.

Gross proceeds from the offering, which is set to close around Thursday, are estimated to be about $200 million.

Underwriters have been granted a 30-day option to purchase up to about 1.7 million additional shares.